NIMH-funded pragmatic trials: Moving on

Neuropsychopharmacology

Volumn 35, Issue 13, 2010, Pages 2489-2490

  Wang, Philip S ^a   Insel, Thomas R ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PSYCHOTROPIC AGENT;

CLINICAL RESEARCH; DRUG RESEARCH; FUNDING; MEDICAL SOCIETY; MENTAL DISEASE; NOTE; PRIORITY JOURNAL;

CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; HUMANS; NATIONAL INSTITUTE OF MENTAL HEALTH (U.S.); RESEARCH SUPPORT AS TOPIC; UNITED STATES;

EID: 78149416938     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/npp.2010.161     Document Type: Note

References (3)

1. March J, Kraemer HC, Trivedi M, Csernansky J, Davis J, Ketter TA et al (2010). What have we learned about trial design from NIMH-funded pragmatic trials? Neuropsychopharmacology 35: 2491-2501.
2. Akil H, Brenner S, Kandel E, Kendler KS, King MC, Scolnick E et al (2010). The future of psychiatric research: genomes and neural circuits. Science 327: 1580-1581.
3. Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR et al (2010). How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat Rev Drug Discov 9: 203-214.